CG Oncology (NASDAQ:CGON) Stock Price Down 6.3% – Should You Sell?

07 Jan 2026, 20:32 by Jessica Moore · The Cerbat Gem

Shares of CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) dropped 6.3% on Monday . The company traded as low as $40.37 and last traded at $39.16. Approximately 124,590 shares traded hands during trading, a decline of 78% from the average daily volume of 562,916 shares. The stock had previously closed at $41.79.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on CGON. Wedbush assumed coverage on CG Oncology in a research note on Thursday, December 11th. They issued an “outperform” rating and a $70.00 price target on the stock. Royal Bank Of Canada increased their price target on shares of CG Oncology from $53.00 to $61.00 and gave the stock an “outperform” rating in a research note on Monday, November 17th. Morgan Stanley boosted their price objective on shares of CG Oncology from $56.00 to $79.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 17th. Guggenheim began coverage on shares of CG Oncology in a research note on Tuesday, October 7th. They set a “buy” rating and a $90.00 target price for the company. Finally, Truist Financial set a $62.00 price target on CG Oncology in a research report on Monday, November 24th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $60.58.

Read Our Latest Analysis on CGON

CG Oncology Stock Up 5.2%

The business’s 50 day moving average price is $41.19 and its 200 day moving average price is $35.04.

CG Oncology (NASDAQ:CGON – Get Free Report) last issued its earnings results on Friday, November 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.57). The company had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.07 million. On average, research analysts anticipate that CG Oncology, Inc. will post -1.31 EPS for the current fiscal year.

Insider Transactions at CG Oncology

In other CG Oncology news, Director James Mulay sold 5,903 shares of the stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $43.99, for a total value of $259,672.97. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Leonard E. Post sold 1,000 shares of the business’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $41.43, for a total value of $41,430.00. The SEC filing for this sale provides additional information. 7.40% of the stock is currently owned by corporate insiders.

Institutional Trading of CG Oncology

Several hedge funds have recently bought and sold shares of the stock. Strengthening Families & Communities LLC purchased a new stake in CG Oncology in the 3rd quarter worth $40,000. Winthrop Capital Management LLC bought a new position in shares of CG Oncology in the second quarter worth about $38,000. Mirae Asset Global Investments Co. Ltd. raised its stake in CG Oncology by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,945 shares of the company’s stock valued at $77,000 after purchasing an additional 398 shares during the period. PNC Financial Services Group Inc. lifted its holdings in CG Oncology by 15.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 3,279 shares of the company’s stock worth $85,000 after purchasing an additional 433 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in CG Oncology in the 3rd quarter worth approximately $211,000. Institutional investors own 26.56% of the company’s stock.

CG Oncology Company Profile

(Get Free Report)

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.